Ntaios G, Savopoulos C, Chatzinikolaou A, Hatzitolios A I
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloniki, Greece.
Acta Neurol Scand. 2008 Dec;118(6):362-6. doi: 10.1111/j.1600-0404.2008.01039.x. Epub 2008 May 27.
Recombinant human erythropoietin was produced soon after the discovery of the erythropoietin gene in 1985 and since then, it is used in various clinical conditions such as chronic renal failure. Moreover, experimental studies have shown that erythropoietin exerts neuroprotective action as well. Recently, a clinical trial yielded promising results concerning the use of erythropoietin in stroke management. In this review, we summarize the main data which suggest that recombinant human erythropoietin and its analogues may indeed have a role in stroke treatment.
1985年发现促红细胞生成素基因后不久，重组人促红细胞生成素就被生产出来，从那时起，它就被用于各种临床病症，如慢性肾衰竭。此外，实验研究表明促红细胞生成素也具有神经保护作用。最近，一项关于促红细胞生成素用于中风治疗的临床试验取得了令人鼓舞的结果。在这篇综述中，我们总结了主要数据，这些数据表明重组人促红细胞生成素及其类似物可能确实在中风治疗中发挥作用。
